542 related articles for article (PubMed ID: 32131439)
1. Hepatocyte Injury and Hepatic Stem Cell Niche in the Progression of Non-Alcoholic Steatohepatitis.
Overi D; Carpino G; Franchitto A; Onori P; Gaudio E
Cells; 2020 Mar; 9(3):. PubMed ID: 32131439
[TBL] [Abstract][Full Text] [Related]
2. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
3. The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression.
Schulien I; Hockenjos B; Schmitt-Graeff A; Perdekamp MG; Follo M; Thimme R; Hasselblatt P
Cell Death Differ; 2019 Sep; 26(9):1688-1699. PubMed ID: 30778201
[TBL] [Abstract][Full Text] [Related]
4. Single-Cell Data Analysis Reveals Critical Hepatic Cells Subpopulations in the Progression of Non-alcoholic Fatty Liver Disease to Non-Alcoholic Steatohepatitis.
Zhao C; Ji G; Zhao X; Ma T; Li Y; Wu W; Zhou L
Comb Chem High Throughput Screen; 2024 May; ():. PubMed ID: 38803181
[TBL] [Abstract][Full Text] [Related]
5. Metabolic drivers of non-alcoholic fatty liver disease.
Bence KK; Birnbaum MJ
Mol Metab; 2021 Aug; 50():101143. PubMed ID: 33346069
[TBL] [Abstract][Full Text] [Related]
6. Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies.
Luci C; Bourinet M; Leclère PS; Anty R; Gual P
Front Endocrinol (Lausanne); 2020; 11():597648. PubMed ID: 33384662
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of cellular plasticity in non-alcoholic steatohepatitis (NASH).
Rajak S
Biochim Biophys Acta Mol Basis Dis; 2024 Apr; 1870(4):167102. PubMed ID: 38422712
[TBL] [Abstract][Full Text] [Related]
8. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
Pierantonelli I; Svegliati-Baroni G
Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of ductular reaction in non-alcoholic steatohepatitis.
Chen Y; Gao WK; Shu YY; Ye J
World J Gastroenterol; 2022 May; 28(19):2088-2099. PubMed ID: 35664038
[TBL] [Abstract][Full Text] [Related]
11. Macrophage Activation in Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) Correlates with Hepatic Progenitor Cell Response via Wnt3a Pathway.
Carpino G; Nobili V; Renzi A; De Stefanis C; Stronati L; Franchitto A; Alisi A; Onori P; De Vito R; Alpini G; Gaudio E
PLoS One; 2016; 11(6):e0157246. PubMed ID: 27310371
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease.
Machado MV; Michelotti GA; Pereira TA; Xie G; Premont R; Cortez-Pinto H; Diehl AM
J Hepatol; 2015 Oct; 63(4):962-70. PubMed ID: 26070409
[TBL] [Abstract][Full Text] [Related]
13. Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease.
Jiao J; Sanchez JI; Saldarriaga OA; Solis LM; Tweardy DJ; Maru DM; Stevenson HL; Beretta L
JHEP Rep; 2023 Feb; 5(2):100628. PubMed ID: 36687470
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of MAP4K4 signaling initiates metabolic reprogramming to protect hepatocytes from lipotoxic damage.
Anand SK; Caputo M; Xia Y; Andersson E; Cansby E; Kumari S; Henricsson M; Porosk R; Keuenhof KS; Höög JL; Nair S; Marschall HU; Blüher M; Mahlapuu M
J Lipid Res; 2022 Jul; 63(7):100238. PubMed ID: 35679904
[TBL] [Abstract][Full Text] [Related]
15. Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid.
Yoo W; Gjuka D; Stevenson HL; Song X; Shen H; Yoo SY; Wang J; Fallon M; Ioannou GN; Harrison SA; Beretta L
PLoS One; 2017; 12(12):e0189965. PubMed ID: 29244873
[TBL] [Abstract][Full Text] [Related]
16. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.
Rosso C; Kazankov K; Younes R; Esmaili S; Marietti M; Sacco M; Carli F; Gaggini M; Salomone F; Møller HJ; Abate ML; Vilstrup H; Gastaldelli A; George J; Grønbæk H; Bugianesi E
J Hepatol; 2019 Nov; 71(5):1012-1021. PubMed ID: 31301321
[TBL] [Abstract][Full Text] [Related]
18. Ductular reaction in non-alcoholic fatty liver disease: When Macbeth is perverted.
He YH; Pan JX; Xu LM; Gu T; Chen YW
World J Hepatol; 2023 Jun; 15(6):725-740. PubMed ID: 37397935
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of Nonalcoholic Steatohepatitis: Interactions between Liver Parenchymal and Nonparenchymal Cells.
Magee N; Zou A; Zhang Y
Biomed Res Int; 2016; 2016():5170402. PubMed ID: 27822476
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte nuclear factor 4α in the pathogenesis of non-alcoholic fatty liver disease.
Pan X; Zhang Y
Chin Med J (Engl); 2022 May; 135(10):1172-1181. PubMed ID: 35191422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
